Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1–Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial
Table 3
Relationship of selected covariates with darunavir or etravirine pharmacokinetic parameters at Week 48—analysis of covariance.
Darunavir
Etravirine
Covariate
Relationship to , estimate (SE)
Relationship to , adjusted value
Relationship to , estimate (SE)
Relationship to , adjusted value
Relationship to , estimate (SE)
Relationship to , adjusted value
Relationship to , estimate (SE)
Relationship to , adjusted value
Sex
0.028 (0.011)
0.011
0.050 (0.016)
0.002
−0.035 (0.049)
0.479
−0.049 (0.063)
0.432
0.246
0.115
0.808
0.843
Asian
–0.099 (0.096)
−0.136 (0.143)
0.369 (0.331)
0.452 (0.422)
Black
–0.002 (0.068)
0.017 (0.101)
0.116 (0.236)
0.155 (0.301)
Hispanic
0.004 (0.069)
0.041 (0.103)
0.148 (0.242)
0.183 (0.308)
White
0.023 (0.069)
0.058 (0.103)
0.130 (0.240)
0.184 (0.306)
Other
0.000
0.000
0.000
0.000
years
0.001 (0.001)
0.005
0.003 (0.001)
<0.001
0.005 (0.002)
0.029
0.007 (0.003)
0.023
kg
0.000 (0.000)
0.839
0.000 (0.000)
0.784
0.002 (0.001)
0.179
0.002 (0.002)
0.149
Use of TDF
–0.019 (0.014)
0.168
–0.038 (0.021)
0.072
NE
NE
NE
NE
Use of etravirine
–0.024 (0.028)
0.389
–0.032 (0.042)
0.450
NA
NA
NA
NA
comparison: white, black, Hispanic, Asian, and other. as continuous linear variables. : area under the plasma concentration–time curve over 12 hours; SE: standard error; : trough concentration; TDF: tenofovir disoproxil fumarate; NE: not evaluated; NA: not applicable.
